drugset
Drugs / Interferon
last change May 2023 re-read 2 minutes ago

Interferon

also known as IFN-alpha2a · hrIFN-a · human recombinant interferon alpha · interferon-alpha2a

Protein / enzyme biologic

Developed for
Alzheimer disease · chronic hepatitis C virus infection · lymphoproliferative syndrome · mycosis fungoides · myeloproliferative neoplasm · neuroblastoma · renal cell carcinoma · Wilms tumor
Investigated by
National Cancer Institute (NCI) · Bayer · M.D. Anderson Cancer Center · Madrilenian Group of Cutaneous Lymphomas · National Center for Research Resources (NCRR) · National Institute of Allergy and Infectious Diseases (NIAID)
+1 more · Pfizer

Trials 7 · a red edge is where a trial was stopped

today NCT00678288 · Ph 2 NCT00324389 · Ph 2 NCT00452023 · Ph 2 NCT00630903 · Ph 4 NCT00001509 · Ph 2 NCT00001438 · Ph 2
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 26 trials
Phase 2 NCT00678288 Apr 2008 → Jun 2009 renal cell carcinoma Bayer Terminated No outcome recorded
Phase 2 NCT00324389 May → Jun 2006 chronic hepatitis C virus infection National Institute of Allergy and Infectious Diseases (NIAID) Completed No outcome recorded
Phase 2 NCT00452023 Apr 2005 → May 2023 myeloproliferative neoplasm M.D. Anderson Cancer Center Completed No outcome recorded
Phase 2 NCT00001509 Jul 1996 → May 2000 Wilms tumor, neuroblastoma National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00001438 Jun 1995 → Dec 2000 HIV infectious disease, immunodeficiency disease, lymphoproliferative syndrome National Cancer Institute (NCI) Completed No outcome recorded
Phase 2 NCT00031018 — Alzheimer disease National Center for Research Resources (NCRR) Unknown No outcome recorded
Phase 41 trial
Phase 4 NCT00630903 Jan 2000 → Jan 2003 mycosis fungoides Madrilenian Group of Cutaneous Lymphomas Terminated No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Interferon “plus Interferon (IFN) alpha-2a 3 millions of international unit (MIU) five times a week (FIW) subcutaneous (s.c.), from Monday to Friday (total weekly dose 15 MIU) s.c., to...” NCT00678288 ↗
Known as hrIFN-a “novel anti-inflammatory agent ingested human recombinant interferon alpha (hrIFN-a)” NCT00031018 ↗
Known as human recombinant interferon alpha “novel anti-inflammatory agent ingested human recombinant interferon alpha (hrIFN-a)” NCT00031018 ↗
Known as IFN-alpha2a “On day 3, a single dose of IFN-alpha 2a (10 MU sc) will be administered and a repeat liver biopsy will be done 24 hours after the injection.” NCT00324389 ↗
6

“The combination of ATRA/IFN-alpha 2a has demonstrated clinical activity in the pediatric phase I trial in neuroblastoma and Wilms' tumor.” NCT00001509 ↗

“IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.” NCT00678288 ↗

“PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides” NCT00630903 ↗

NCT00001438 ↗

NCT00452023 ↗

NCT00031018 ↗
Known as interferon-alpha2a “an immunomodulatory agent (interferon-alpha2a, IFN-alpha2a)” NCT00001438 ↗
Modality Protein / enzyme biologic “novel anti-inflammatory agent ingested human recombinant interferon alpha (hrIFN-a)” NCT00031018 ↗
Route Oral “IFNs administered by the oral route show a systemic effect” NCT00031018 ↗